drugset / Trial / NCT07136077
A Phase 2 Trial of Fruquintinib and Tislelizumab in ctDNA-defined Minimal Residual Disease in Colorectal Cancer After Completion of Adjuvant Chemotherapy
Phase 2
Recruiting
20 enrolled
M.D. Anderson Cancer Center
BeiGene · collabTakeda Pharmaceutical Co. Limited · collab
Non-randomizedSingle-groupOpen-labelTreatment
Summary
To find out if a combination of fruquintinib and tislelizumab can control CRC in patients who have received treatment for the disease but still have "positive" ctDNA tests for MRD (meaning there is evidence of MRD based on this test).
Timeline
- Start
- 2025-09-18
- Primary completion
- 2027-12-01
- Completion
- 2028-04-01
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Fruquintinib | Small molecule | — | Oral |
| Subject | Tislelizumab | Monoclonal antibody | — | Intravenous |